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Aims To compare the efﬁcacy and safety of drug-eluting stents vs. bare-metal stents in patients with
acute ST-segment elevation myocardial infarction.
Methods and results We performed a meta-analysis of eight randomized trials comparing drug-eluting
stents (sirolimus-eluting or paclitaxel-eluting stents) with bare-metal stents in 2786 patients with acute
ST-segment elevation myocardial infarction. All patients were followed up for a mean of 12.0–
24.2 months. Individual data were available for seven trials with 2476 patients. The primary efﬁcacy
endpoint was the need for reintervention (target lesion revascularization). The primary safety endpoint
was stent thrombosis. Other outcomes of interest were death and recurrent myocardial infarction. Drug-
eluting stents signiﬁcantly reduced the risk of reintervention, hazard ratio of 0.38 (95% CI, 0.29–0.50),
P , 0.001. The overall risk of stent thrombosis: hazard ratio of 0.80 (95% CI, 0.46–1.39), P ¼ 0.43;
death: hazard ratio of 0.76 (95% CI, 0.53–1.10), P ¼ 0.14; and recurrent myocardial infarction:
hazard ratio of 0.72 (95% CI, 0.48–1.08, P ¼ 0.11) was not signiﬁcantly different for patients receiving
drug-eluting stents vs. bare-metal stents.
Conclusion The use of drug-eluting stents in patients with acute ST-segment elevation myocardial
infarction is safe and improves clinical outcomes by reducing the risk of reintervention compared
with bare-metal stents.
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Introduction
Primary percutaneous coronary intervention (PCI) is the pre-
ferred reperfusion strategy for patients presenting with
acute myocardial infarction with ST-segment elevation.1,2
Compared with balloon angioplasty, routine implantation
of bare-metal stents has been associated with improved
clinical outcome mainly because of the decreased risk for
reintervention.3,4 Nevertheless, restenosis remains an
important limitation of the use of bare-metal stents in
patients with acute myocardial infarction.4–7
Drug-eluting stents effectively reduce restenosis while
maintaining a good safety proﬁle in many lesion and patients
groups.8,9 However, concerns have been raised with regard
to the safety of drug-eluting stents in patients with acute
myocardial infarction.10 Data from registry studies have
suggested that implantation of drug-eluting stents during
primary PCI could be associated with an increased risk for
stent thrombosis, which is associated with high-morbidity
and -mortality rates.11,12 Recently, the results of several
randomized trials of drug-eluting stents in patients under-
going primary PCI for acute ST-segment elevation myo-
cardial infarction have been reported. These studies had,
however, insufﬁcient power to assess the risk of rare
adverse events. Furthermore, they did not consistently
show the superior effectiveness of drug-eluting stents in
that particular setting.13–15 Meta-analyses of randomized
trials have the potential to increase the power and
improve the precision of treatment effects.16 A meta-
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analysis has recently been published including seven ran-
domized trials with a total number of 2357 patients.17
However, this meta-analysis was based on summary data ex-
tracted from meeting abstracts in four of the seven trials.17
Toma et al.18 suggest caution in the use of these data
because of common discrepancies in results between
meeting abstracts and subsequent full-length publications.
A meta-analysis on the basis of individual patient data
yields much more accurate results and is the ‘gold standard’
to perform time-to-event analyses.19
We performed a meta-analysis predominantly based on
individual patient data from randomized trials comparing
drug-eluting stents with bare-metal stents to evaluate the
efﬁcacy and safety of drug-eluting stents in patients with
acute ST-segment elevation myocardial infarction.
Methods
Literature search
We performed an electronic search of the United States National
Library of Medicine (PubMed, at http://www.pubmed.gov), the
United States National Institutes of Health clinical trials registry
(http://www.clinicaltrials.gov), and the Cochrane Central Register
of Controlled Trials (http://www.mrw.interscience.wiley.com/
cochrane/cochrane_clcentral_articles_fs.html). The key words
used included ‘myocardial infarctio’, ‘primar’, ‘angioplast’, ‘PC’,
‘ST-segment elevatio’, ‘drug-eluting sten’, sirolimus-‘eluting
sten’, ‘paclitaxel-eluting sten’, ‘clinical tria’, and ‘randomize’.
Internet-based sources of information on the results of clinical
trials in cardiology (http://www.cardiosource.com/clinicaltrials,
http://www.theheart.org, and http://www.clinicaltrialresults.com,
and http://www.tctmd.com) were also searched. Additional data
sources included conference proceedings from the American
College of Cardiology, American Heart Association, and European
Society of Cardiology meetings. We also identiﬁed relevant reviews
and editorials from major medical journals published within the
last year and assessed for possible information on trials of interest.
The search period was between January 2002 and February 2007.
Study selection
To be selected for this meta-analysis, studies comparing
drug-eluting stents with bare-metal stents in patients undergoing
primary PCI of ST-segment elevation acute myocardial infarction
had been randomized and had their results reported or made avail-
able by the trial investigators for a mean follow-up period of at least
12 months. Articles were searched and reviewed independently by
two of the authors (A.D. and J.M.); those meeting the inclusion cri-
teria were selected for further analysis. A total of nine trials were
identiﬁed. The trial of Pasceri et al.20 was excluded because it
reported only preliminary data of the ﬁrst 34 patients over a
follow-up of 4+2 months. Finally, eight trials were included in
this meta-analysis (Figure 1).13–15,21–25
Study outcomes and data collection
The primary efﬁcacy endpoint of this meta-analysis was the need of
reintervention (target lesion revascularization). The primary safety
endpoint of this meta-analysis was stent thrombosis. Secondary end-
points were death and recurrent myocardial infarction. The compo-
site of death, recurrent myocardial infarction, or reintervention was
also assessed. The event deﬁnitions used in individual trials are
given in Table 1. The adjudication of events in each trial was per-
formed by the same event committee over the entire follow-up
period. Survival was calculated from the date of randomization to
the date of death. Data for surviving patients were censored on
the date of last follow-up.
An electronic form containing the data ﬁelds to be completed for
individual patients was sent to all principal investigators of
the trials. Individual patient data could be obtained for seven
trials.13–15,21–24
The data requested for each enrolled patient included the date of
randomization, allocated treatment, diabetes status, event status
[including death, myocardial infarction, coronary reintervention
(percutaneous or surgical), stent thrombosis, and their respective
dates of occurrence], and date of last follow-up. All data were
thoroughly checked for consistency (logical checking and checking
against the original publications). Any queries were resolved and
the ﬁnal database entries were veriﬁed by the responsible trial
investigator.
Each trial was evaluated for the adequacy of allocation conceal-
ment, performance of the analysis according to the intention-
to-treat principle, and blind assessment of the outcomes of interest.
We used the criteria recommended by Altman et al.26 and Ju¨ni
et al.27 to assess the adequacy of allocation concealment. In two
trials, a modiﬁed intention-to-treat principle, i.e. exclusion of
patients who did not receive the study stent, was used.14,25
Statistical methods
We performed survival analyses using the Mantel–Cox method
stratiﬁed by trial. The log-rank test was used to calculate hazard
ratios and their 95% CIs.
Trials in which the event of interest was not observed in either
treatment group were discarded from the analysis of that event.
In case, only one of the groups of an individual trial had no event
of interest, the treatment effect estimate and its standard error
were calculated after adding 0.5 to each cell of the 2  2 table
for that trial.28
We used the Cochran’s test to assess the heterogeneity across
trials. We also calculated the I2 statistic to measure the consistency
among trials with values of 25, 50, and 75% showing, respectively,
low, moderate, and high heterogeneity.29 Hazard ratios from
Figure 1 Flowchart of selected studies. BMS, bare-metal stent; DES,
drug-eluting stent; RCT, randomized control trial.
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Table 1 Endpoint deﬁnitions in each trial
Study Death Recurrent myocardial infarction Reintervention Stent thrombosis
BASKET-AMI22 Cardiac, if clearly
due to a cardiac
event, otherwise
non-cardiac
Typical chest pain with either
typical rise (and fall) of cardiac
enzymes or new pathologic
Q-waves/ST-Twave changes on
ECG
Intervention (PCI or CABG)
driven by a lesion in the
same epicardial vessel as
initially treated
Angiographic evidence in the
presence of an ischaemic
clinical event
Di Lorenzo21 Cardiac unless a
non-cardiac
cause could be
identiﬁed
Recurrence of anginal symptoms
with typical ECG changes and
increase of CK-MB or troponin
Any CABG or PCI of the
target vessel in the
presence of symptoms or
signs of ischemia
Angiographically documented
thrombus within the stent
associated to typical chest
pain and ST-segment
modiﬁcation in the territory
of the infarct related vessel
with or without a signiﬁcant
rise of enzymes
HAAMU-STENT23 Cardiac if sudden
unexpected
death or
witnessed fatal
arrhythmia or
cardiac failure
Clinical picture of myocardial
infarction with ST-segment
changes and elevated cardiac
markers or angiographic stent
thrombosis
Any CABG of the target
vessel or a PCI because of
angiographic restenosis
in the presence of
symptoms or signs of
ischaemia
Acute ST-segment elevation
myocardial infarction plus
angiographic thrombus
MISSIONa25 Cardiac unless a
non-cardiac
cause could be
identiﬁed
Development of new Q-waves on
ECG or a troponin-T rise above
normal (.25% above previous
value) with symptoms or need
for reintervention
Any CABG or PCI of the
target vessel
Angiographically documented
thrombus within the stent
and/or typical chest pain
with recurrent ST-segment
elevation in the territory of
the infarct-related vessel in
combination with a
signiﬁcant rise of troponin
levels and/or the presence
of new Q-waves in the
territory of the
infarct-related vessel
PASSION13 Cardiac unless a
noncardiac cause
could be
identiﬁed
Either pathological Q-waves on
ECG or an increase in the
creatine kinase level 2 times
the upper normal level or
.50% the previous value (if
they were still elevated) with
symptoms or need for
reintervention
Any CABG of the target
vessel or a PCI because of
angiographic restenosis
in the presence of
symptoms or signs of
ischaemia
Angiographic documentation
of either vessel occlusion or
thrombus formation within,
or adjacent to, the stented
segment
SESAMI24 Cardiac unless an
unequivocal
non-cardiac
cause could be
established
Recurrent ischaemic symptoms or
ECG changes accompanied by
an increase in cardiac enzymes
2 times the upper normal
level (if values were previously
normalized) or .50% the
previous value (if they were
still elevated)
Any CABG of the target
vessel or a PCI due to
angiographic restenosis
in the presence of
symptoms or signs of
ischemia
Angiographic evidence in the
presence of an acute
coronary syndrome
STRATEGY15 Cardiac unless an
unequivocal
non-cardiac
cause could be
established
Recurrent ischaemic symptoms or
ECG changes accompanied by
an increase in cardiac enzymes
above the normal limit (if
values were previously
normalized) or .50% the
previous value (if they were
still elevated)
Any CABG or PCI of the
target vessel in the
presence of symptoms or
signs of ischaemia
Angiographic evidence in the
presence of clinical
symptoms or ECG changes
suggestive of acute
ischaemia
Continued
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individual trials were pooled using the DerSimonian and Laird
method for random effects.30
We performed sensitivity analyses by comparing the treatment
effects obtained with each trial removed consecutively from the
analysis with the overall treatment effects. Results were considered
statistically signiﬁcant at two-sided P , 0.05. Statistical analysis
was performed using the Stata software, version 9.2 (Stata Corp,
College Station, TX, USA). Survival curves are presented as
simple, non-stratiﬁed Kaplan–Meier curves across all trials and
constructed with the use of S-Plus software version 4.5. (Insightful
Corporation, Seattle, WA, USA).
Results
Eight trials with 2786 patients were included in this
meta-analysis. The main characteristics of these trials are
summarized in Table 2. The mean age of participants in indi-
vidual trials varied from 59.2 to 64.0 years. Drug-eluting
stents consisted of paclitaxel-eluting stents in two of the
trials and sirolimus-eluting stents in four other trials; in
the remaining two trials, a three-arm design was used
including both paclitaxel-eluting and sirolimus-eluting
stents.21,22 The recommended length of post-procedural
thienopyridine therapy was 315, 613,14,21,22 or 12 months.23–25
The mean length of follow-up ranged from 12.0 to
24.2 months. Patient-level data were available for seven
trials with 2476 patients.13–15,21–24
Figure 2A shows the number of patients who experienced
the primary efﬁcacy endpoint of reintervention according to
the treatment group, with the hazard ratio for each of the
trials. Overall, the use of drug-eluting stents was associated
with a hazard ratio of 0.38 for reintervention (95% CI, 0.29–
0.50), P, 0.001, compared with the use of the bare-metal
stent. There was no heterogeneity across trials (I2 ¼ 0%) and
no signiﬁcant interaction (P ¼ 0.07) between the effect of
treatment and the type of drug-eluting stent (sirolimus-eluting
stent or paclitaxel-eluting stent) used. Sequential exclusion of
each individual trial from the analysis of the primary endpoint
yielded hazard ratios ranging from 0.33 (95% CI, 0.24–0.45) to
0.42 (95%CI, 0.30–0.57),whichwere not signiﬁcantly different
from the overall hazard ratio. Speciﬁcally, the hazard ratio for
reintervention associated with the use of drug-eluting stents
was 0.39 (95% CI, 0.29–0.53) when the trial for which no indi-
vidual patient data were available was excluded.25 Figure 2B
shows 1-year probability curves for reintervention in the two
treatment arms. An early and continuous separation of the
curves is readily visible. The probability of reintervention
was 5.0% in the drug-eluting stent group and 13.3% in the bare-
metal stent group.
Figure 3A shows the number of patients who suffered the
primary safety endpoint of stent thrombosis according to the
treatment group, with the hazard ratio for each of the trials.
The hazard ratio for stent thrombosis was 0.80 (95% CI,
0.46–1.39), P ¼ 0.43. There was no heterogeneity across
trials (I2 ¼ 0%) and no signiﬁcant interaction (P ¼ 0.89)
between the effect of treatment and the type of
drug-eluting stent used (sirolimus-eluting stent or
paclitaxel-eluting stent). In addition, the hazard ratio for
stent thrombosis associated with the use of drug-eluting
stents was 0.82 (95% CI, 0.46–1.47) when the trial for
which no individual patient data were available was
excluded.25 Figure 3B shows 1-year curves of stent thrombo-
sis probability for the two treatment groups. The probability
of stent thrombosis was 1.6% in the drug-eluting stent group
and 2.2% in the bare-metal stent group. Three stent throm-
boses occurred after 1 year: two in the drug-eluting stent
group and one in the bare-metal stent group.
Figure 4A shows the number of patients who died according
to the treatment group, with the hazard ratio for each of the
trials. There was no heterogeneity across the trials (I2 ¼ 1%)
and no signiﬁcant interaction (P ¼ 0.48) between the effect
of treatment and the type of drug-eluting stent used.
Overall, the use of the drug-eluting stent was associated
with a hazard ratio of 0.76 for death (95% CI, 0.53–1.10),
P ¼ 0.14, compared with the use of the bare-metal stent.
Table 1 Continued
Study Death Recurrent myocardial infarction Reintervention Stent thrombosis
TYPHOONa14 Cardiac if a cardiac
cause cannot be
excluded
Recurrence of clinical symptoms
or the occurrence of
electrocardiographic changes
accompanied by a new
elevation of cardiac enzymes
(1.5 times the previous value
or three times the upper limit
of normal)
Any CABG of the target
vessel or a PCI because of
angiographic restenosis
in the presence of
symptoms or signs of
ischaemia, or only
because of severe
restenosis (70%
diameter stenosis)
Acute and subacute stent
thromboses were deﬁned as
angiographic proof of vessel
occlusion, any recurrent
Q-wave myocardial
infarction in the territory of
the stented vessel, or any
death from cardiac causes.
Late stent thrombosis was
deﬁned as any recurrent
myocardial infarction with
angiographic proof of vessel
occlusionb
CABG, aorto-coronary bypass surgery; PCI, percutaneous coronary intervention; HAAMU-STENT, The Helsinki area acute myocardial infarction-treatment
re-evaluation—should the patient get a drug-eluting or a normal stent trial; MISSION, a prospective randomized controlled trial to evaluate the efﬁcacy
of drug-eluting stents vs. bare-metal stents for the treatment of acute myocardial infarction; PASSION, the paclitaxel-eluting stent vs. conventional stent
in myocardial infarction with ST-segment elevation trial; SESAMI, the randomized trial of sirolimus stent vs. bare stent in acute myocardial infarction
trial; STRATEGY, the single high-dose bolus Tiroﬁban and sirolimus eluting stent vs. Abciximab and bare-metal stent in myocardial infarction trial;
TYPHOON, the trial to assess the use of the Cypher stent in acute myocardial infarction treated with balloon angioplasty.
aA ‘modiﬁed intention-to-treat’ principle was adopted in the trial, i.e. a randomized patient was included in the analysis only if he received stent(s).
bAccording to protocol, patients undergoing reintervention had to be censored from further assessment of stent thrombosis.
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Ninety-eight of the 121 death cases (81.0%) observed in seven
trials for which patient-level data were available were of
cardiac origin, without any signiﬁcant difference between
the drug-eluting stent group (45 of 58 cases) and bare-metal
stent group (53 of 63 cases), P ¼ 0.36. Figure 4B shows the
1-year mortality curves for the two treatment groups. The
probability of death was 4.0% in the drug-eluting stent group
and 5.0% in the bare-metal stent group. Twelve patients died
after 1 year: six in the drug-eluting stent group and six in the
bare-metal stent group.
Figure 5A shows the absolute numbers of patients who
suffered a recurrent myocardial infarction according to the
treatment group, with the hazard ratio for each of these
trials. No evidence of heterogeneity was observed across the
trials (I2¼ 0%). Overall, the use of the drug-eluting stent was
associated with a hazard ratio of 0.72 for the recurrent myocar-
dial infarction (95% CI, 0.48–1.08), P¼ 0.11, comparedwith the
use of the bare-metal stent. Figure 5B shows 1-year probability
curves for recurrentmyocardial infarction for the two treatment
arms. The probability of recurrent myocardial infarction was
2.5% in the drug-eluting stent group and 3.3% in the bare-metal
stent group.
The composite of death, recurrent myocardial infarction,
or reintervention was observed in 158 of the 1474 patients in
the drug-eluting stent group and 252 of the 1312 patients in
the bare-metal stent group. The use of the drug-eluting
stent was associated with a hazard ratio of 0.53 for this
composite endpoint (95% CI, 0.42–0.67), P , 0.001, com-
pared with the use of the bare-metal stent. The probability
of the composite of death, recurrent myocardial infarction,
or reintervention was 9.5% in the drug-eluting stent group
and 17.8% in the bare-metal stent group.
Discussion
In this study, we performed a meta-analysis of eight random-
ized trials comparing drug-eluting stents with bare-metal
stents in patients with acute ST-segment elevation myocar-
dial infarction. We found no signiﬁcant differences in the
risk of stent thrombosis, death, or recurrent myocardial
infarction between patients treated with drug-eluting
stents vs. bare-metal stents. On the other hand, we found
that treatment with drug-eluting stents was associated
with a 62% reduction in the hazard of reintervention com-
pared with bare-metal stents. The advantage of drug-eluting
stents was notable within the ﬁrst month after stent implan-
tation procedure and continued to increase thereafter.
A large number of studies have shown that the use of
drug-eluting stents is associated with favourable outcomes
in patients with various clinical and angiographic character-
istics.9,31 However, data on the outcome of patients under-
going primary PCI with implantation of drug-eluting stents
have been limited, and whether the favourable results
obtained with drug-eluting stents in other settings also
Table 2 Main characteristics of the trials
Study No. of
patients
Mean
age
(years)
Type
of DES
Availability of
individual
patient data
Primary endpoint Length of
thienopyridine
therapy (months)
Mean length of
follow-up
(months)
BASKET-AMI22 216 62.2 PES Yes Cardiac death,
myocardial infarction,
or reintervention
6 18.0
SES
Di Lorenzo21 270 64.0 PES Yes Death, myocardial
infarction, or
reintervention
6 12.0
SES
HAAMU-STENT23 164 63.0 PES Yes Angiographic late lumen
loss
12 16.7
MISSION25 310 59.2 SES No Angiographic late lumen
loss
12 12.0
PASSION13 619 60.8 PES Yes Cardiac death,
myocardial infarction,
or reintervention
6 12.0
SESAMI24 320 61.6 SES Yes Angiographic binary
restenosis
12 12.3
STRATEGY15 175 62.6 SES Yes Death, myocardial
infarction, stroke, or
angiographic binary
restenosis
3 24.2
TYPHOON14 712 59.3 SES Yes Cardiac death,
myocardial infarction,
or reintervention
6 12.1
DES, drug-eluting stent; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent; BASKET-AMI, Basel Stent Kosten Effektivita¨ts in Acute Myocardial Infarc-
tion trial; HAAMU-STENT, The Helsinki area acute myocardial infarction-treatment re-evaluation—should the patient get a drug-eluting or a normal stent
trial; MISSION, A prospective randomized controlled trial to evaluate the efﬁcacy of drug-eluting stents vs. bare-metal stents for the treatment of acute
myocardial infarction; PASSION, the Paclitaxel-eluting stent vs. conventional stent in myocardial infarction with ST-segment elevation trial; SESAMI, the ran-
domized trial of sirolimus stent vs. bare stent in acute myocardial infarction trial; STRATEGY, the single high-dose bolus tiroﬁban and sirolimus eluting stent
vs. Abciximab and bare-metal stent in myocardial infarction trial; TYPHOON, the trial to assess the use of the Cypher stent in acute myocardial infarction
treated with balloon angioplasty.
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extend to patients with acute ST-segment elevation myocar-
dial infarction has not been ﬁrmly established. A major
concern with drug-eluting stents in this group of patients
has been an increased risk for stent thrombosis, especially
acute (within 24 h of stent implantation) and subacute
(within 30 days of stent implantation).10 There is an
increased platelet activation in acute coronary syndromes,
especially in acute myocardial infarction,32 and coronary
stenting is associated with a more intense platelet acti-
vation than balloon angioplasty alone.33 A greater platelet
activation coupled to delayed healing, lack of endotheliali-
zation, and exposure of proinﬂammatory and prothrombo-
genic environment of the necrotic core could provide
the rationale for an increased risk of drug-eluting stent
thrombosis in patients with acute myocardial infarction.10
Recently, Park et al.12 found that primary stenting with
implantation of sirolimus-eluting or paclitaxel-eluting stents
in patients with acute myocardial infarction was a major
predictor for acute and subacute stent thrombosis.
However, registry studies of patients with acute ST-segment
elevation myocardial infarction have not shown an increased
risk of stent thrombosis with drug-eluting stents compared
with bare-metal stents.34–36
In our meta-analysis, the incidence of stent thrombosis was
similar among patients treated with drug-eluting stents vs.
bare-metal stents, as was the incidence of death or recurrent
myocardial infarction. These ﬁndings support the safety of
use of these types of stents. However, they should be inter-
preted with caution. Despite the advantage conferred by
meta-analysis that has the potential to increase the statistical
power, the rare occurrence of the previously discussed
adverse events might limit the capacity of this meta-analysis
to detect a possible difference between the two treatment
arms with regard to the safety outcomes. Larger studies with
a longer follow-up period will be needed to deﬁnitely answer
the question of whether primary stenting with drug-eluting
stents is safe.37,38
In conclusion, the results of this meta-analysis show that
the use of drug-eluting stents in patients undergoing PCI
for acute ST-segment elevation myocardial infarction is
safe and improves clinical outcomes by reducing the risk of
reintervention compared with bare-metal stents.
Figure 2 (A) Absolute numbers of patients requiring reintervention and
hazard ratios for this endpoint with drug-eluting stents vs. bare-metal
stents for individual trials and the pooled population. Hazard ratios are
shown on a logarithmic scale. The size of the square is proportional to the
weight of the individual studies, measured as the inverse of the estimated
variance of the log hazard ratio. DES, drug-eluting stent; BMS, bare-metal
stent. (B) Kaplan–Meier curves of reintervention in each of the stent groups
for the pooled population.
Figure 3 (A) Absolute numbers of patients with stent thrombosis and hazard
ratios for stent thrombosis associated with drug-eluting stents vs. bare-metal
stents for individual trials and the pooled population. Hazard ratios are shown
on a logarithmic scale. The size of the square is proportional to the weight of
the individual studies, measured as the inverse of the estimated variance of
the log hazard ratio. DES, drug-eluting stent; BMS, bare-metal stent. (B)
Kaplan–Meier curves of stent thrombosis in the pooled population according
to stent type.
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